- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02585388
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (CHEOPS)
September 5, 2023 updated by: ARCAGY/ GINECO GROUP
A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amilly, France, 45207
- Centre Hospitalier de l'Agglomération Montargoise
-
Angers, France, 49933
- ICO Paul Papin
-
Avignon, France, 84918
- Institut Sainte-Catherine
-
Bayonne, France, 64109
- Centre Hospitalier de la Cote Basque
-
Bourg-en-Bresse, France, 01000
- Centre Hospitalier Fleyriat
-
Brest, France, 29200
- Clinique Pasteur
-
Brest, France, 29200
- CHU de Brest
-
Contamine sur Arve, France, 74130
- Centre Hospitalier Alpes Léman
-
Draguignan, France, 83300
- CH de la Dracénie
-
Gap, France, 05007
- Centre Hospitalier Intercommunal des Alpes du Sud
-
Grenoble, France, 38043
- CHU de Grenoble
-
Grenoble, France, 38028
- Groupe Hospitalier Mutualiste de Grenoble
-
Guilherand-granges, France, 07500
- Hôpital privé Drôme Ardèche - Clinique Pasteur
-
Guilhérand-Granges, France, 07500
- Hôpital privé Drôme Ardèche
-
La Roche sur Yon, France, 85925
- CHD Vendée
-
Laon, France, 02000
- Centre Hospitalier de Laon
-
Le Coudray, France, 28630
- CH Chartres Hôpital Louis Pasteur
-
Le Mans, France, 72000
- Centre Hospitalier Le Mans
-
Lyon, France, 69008
- Centre Leon Berard
-
Lyon, France, 69008
- Hopital Privé Jean Mermoz
-
Lyon, France, 69373
- Hopital Privé Jean Mermoz
-
Mont de Marsan, France, 40000
- CH Layne
-
Montélimar, France, 26216
- CH Montélimar
-
Mougins, France, 06250
- Centre Azuréen de Cancérologie
-
Nancy, France, 54000
- Oracle
-
Nantes, France, 44202
- Centre Catherine De Sienne
-
Orléans, France, 45100
- CHR Orleans
-
Pau, France, 64000
- Centre Hospitalier de Pau
-
Perigueux, France, 24000
- Polyclinique Francheville
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
Plérin, France, 22191
- Hopital Privé des Cotes d'Armor
-
Pringy, France, 74374
- Centre Hospitalier Annecy-Genevois
-
Pringy, France, 74374
- Centre Hospitalier de la Région d'Annecy
-
Quimper, France, 29107
- Centre Hospitalier de Quimper
-
Reims, France, 51726
- Institut Jean Godinot
-
Reims, France, 51100
- Institut du Cancer Courlancy Reims
-
Romans sur Isère, France, 26100
- Centre Hospitalier de Romans sur Isère
-
Romans-sur-isere, France, 26100
- Hôpitaux Drôme Nord - Site de Romans
-
Saint Grégoire, France, 35750
- CHP Saint Gregoire
-
Saint Priest en Jarez, France, 42271
- Institut de Cancerologie Lucien Neuwirth
-
Soissons, France, 02200
- Centre Hospitalier de Soissons
-
St Herblain, France, 44800
- ICO Gauducheau
-
St Jean de Luz, France, 64501
- Polyclinique Côte Basque Sud
-
Strasbourg, France, 67091
- Hopitaux Universitaires De Strasbourg
-
Thonon-Les-Bains, France, 74200
- Hôpitaux du Léman
-
Valenciennes, France, 59322
- Centre Hospitalier Jean Bernard
-
Vandoeuvre Les Nancy, France, 54519
- Institut de Cancérologie de Lorraine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 50 years.
- Histologically proven breast cancer.
- Progesterone and /or oestrogene receptors positive.
- HER2 negative on primary tumour.
- Patient taking hormonotherapy, in progression, already treated by at least one line of anti-aromatase non-steroidal hormonotherapy and by at least on line of chemotherapy.
- Patient having to begin a second or third line of chemotherapy.
- Presence of one or several measurable(s) or assessable(s) metastatic lesion(s).In case of isolated bone lesion (s): need to have a non-irradiated with an osteolytic component for be considered as lesion (s) target (s) and having an elevation of the CA15-3.
- Post menopausal woman.
- ECOG 0, 1 or 2.
Adequate biological function.
- Neutrophil ≥ 1,5.E9/L
- Platelets ≥ 100.E9/L
- Creatinine clearance ≥ 30 mL/min
- Total bilirubin ≤ 1,5 x the upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2,5 x ULN
- ALT, AST ≤ 1,5 x ULN in the absence of liver metastases or ≤ 3 x ULN if liver metastases.
- Patient with a life expectancy greater than 3 months.
- Signed informed consent before enrollment.
- affiliation to a social security scheme
Exclusion Criteria:
- Patient with located or single metastatic tumoral relapse, accessible to a surgical treatment.
- Patient having already received more 2 lines of chemotherapy for metastatic or advanced decease
- Patient having already received a treatment by Navelbine®
- Patient requiring an immediate located radiotherapy for analgesic action
- Patient with non-irradiated cerebral or symptomatic metastasis, symptomatic pulmonary carcinomatosis lymphangitis
- Simultaneous administration of another chemotherapy hormonotherapy or anti-tumoral drug
- Patient having already received another treatment ongoing evaluation within the 30 days before the screening visit
- Known positive serology HIV
- Previous cancer within 5 years before the entry in the study, excepted an in situ carcinoma of the cervix or a spino or basal cell carcinoma of the skin or a nonmelanoma skin cancer with an adequate treatment.
- Any serious concomitant pathology and / or uncontrolled could compromise participation in the study (including uncontrolled diabetes, uncontrolled hypertension, severe infection, profound malnutrition, unstable angina or congestive heart failure - class III or IV according to the New York Heart Association - ventricular arrhythmias, progressive coronary artery disease, myocardial infarction within the last six months, chronic liver or kidney disease, a progressive ulceration of the digestive tract above, CNS disorders).
- Disorder of gastrointestinal function (GI) or pathology likely to significantly interfere with the absorption of Navelbine, of Letrozole or Anastrozole (eg. Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, syndrome malabsorption, or resection of the small intestine).
- Known hypersensitivity to letrozole, anastrozole, vinorelbine or other vinco-alkaloids or any other component.
- Patient with fructose intolerance, galactose, a Lapp lactase deficiency or malabsorption of glucose and galactose (rare hereditary disease).
- Patient with a history of poor compliance with medical treatment.
- Patient can not be monitored regularly for family reasons, geographical, social or psychological.
- Patient with altered mental status would not allow him to understand the study or give informed consent .
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vinorelbine
Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
|
Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week.
One dose level reduction is authorized at 30 mg per day.when
stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
Other Names:
|
Experimental: Vinorelbine+Anastrozole or Letrozole
Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity. And: Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity |
Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week.
One dose level reduction is authorized at 30 mg per day.when
stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
Other Names:
Lestrozole at 2,5 mg every day , per oral
Other Names:
Anastrozole at 1 mg every day, per oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: up to 6 months
|
Proportion of progression or death
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of partial and complete response rate by RECIST 1.1
Time Frame: up to 6 months
|
partial and complete response rate by RECIST 1.1 in each arm
|
up to 6 months
|
duration of response
Time Frame: up to 6 months
|
duration of response is defined as the time from randomization and the disease progression
|
up to 6 months
|
clinical benefit after 24 weeks of treatment
Time Frame: up to 24 weeks
|
the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1
|
up to 24 weeks
|
overall survival
Time Frame: up to 2 years
|
the overall survival of patients randomized is defined as the time from randomization and the date of death
|
up to 2 years
|
Toxicity according to criteria NCI CTAEv4.03
Time Frame: up to 2 years
|
tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03
|
up to 2 years
|
health-related quality of life
Time Frame: up to 2 years
|
health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Pierre-Etienne HEUDEL, MD, Centre Leon Berard
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2015
Primary Completion (Actual)
May 15, 2017
Study Completion (Actual)
May 15, 2017
Study Registration Dates
First Submitted
October 22, 2015
First Submitted That Met QC Criteria
October 22, 2015
First Posted (Estimated)
October 23, 2015
Study Record Updates
Last Update Posted (Actual)
September 6, 2023
Last Update Submitted That Met QC Criteria
September 5, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Vinorelbine
- Anastrozole
Other Study ID Numbers
- GINECO-BR112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Vinorelbine
-
Henan Cancer HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingBreast Cancer | Breast Diseases | HER2-positive Breast Cancer | Vinorelbine | PyrotinibChina
-
QLT Inc.TerminatedStage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
-
Merck KGaA, Darmstadt, GermanyCompletedNon Small Cell Lung Cancer (NSCLC)Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
-
Southern Europe New Drug OrganizationPierre Fabre Laboratories; AgennixUnknown
-
University of AarhusPierre Fabre LaboratoriesCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Liaoning Tumor Hospital & InstituteNot yet recruitingTriple-negative Breast Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed